CLINICAL_TRIALS
trial_result
· 2007-12-18
Clinical Trial Update: Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment [Phase 2]
Summary
Phase 2 study of Ovarex (Oregovomab) monoclonal antibody with front-line chemotherapy for ovarian cancer has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Unither Pharmaceuticals | Conditions: Ovarian Cancer | Phase 2 | Status: TERMINATED